Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HROWM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
NA
vs NA
Q2.23
N/A
NA
vs NA
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs NA
Q2.24
N/A
NA
vs NA
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
-0.05
vs NA
Q2.25
N/A
0.01
vs NA
Sales Growth
YoY
Current
Estimates
Q1.23
+18%
26.1M vs 22.1M
Q2.23
+44%
33.5M vs 23.3M
Q3.23
+50%
34.3M vs 22.8M
Q4.23
+79%
36.4M vs 20.3M
Q1.24
+33%
34.6M vs 26.1M
Q2.24
+46%
48.9M vs 33.5M
Q3.24
+44%
49.3M vs 34.3M
Q4.24
+84%
66.8M vs 36.4M
Q1.25
+65%
57M vs 34.6M
Q2.25
+35%
66M vs 48.9M
Return on Equity
QoQ
Q1.23
-30%
-0.30
vs 0.04
Q2.23
-19%
-0.19
vs -0.30
Q3.23
-6%
-0.06
vs -0.19
Q4.23
-13%
-0.13
vs -0.06
Q1.24
-23%
-0.23
vs -0.13
Q2.24
-11%
-0.11
vs -0.23
Q3.24
-7%
-0.07
vs -0.11
Q4.24
+10%
0.1
vs -0.07
Institutionnal Ownership
Forecast
328%2025-Revenue
-24%2025-EPS
-83%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
NASDAQ
0.01Â ( 0.04%)
Relative Strenght
40
Volume Buzz
116%
Earning Acce
Yes
Dist 52w H.
4%Relative Strength
HROWM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How HROWM compares to sector?